Record Information
Version1.0
Creation Date2009-07-21 20:26:25 UTC
Update Date2026-05-14 16:24:59 UTC
Accession NumberCHEM002155
Identification
Common NameClotrimazole
ClassSmall Molecule
Description
Clotrimazole is an imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. There is the potential for drug interactions with Clotrimazole if taken orally, as it is a potent, specific inhibitor of cytochrome P450 oxidase enzymes and so may alter the metabolism of other drugs. Clotrimazole is an antifungal medication commonly used in the treatment of fungal infections of both humans and animals such as vaginal yeast infections and ringworm. An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal cell membranes. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Clotrimazole is a potent, specific inhibitor of cytochrome P450 oxidase enzymes. Hence, it may alter the metabolism of other drugs particularly if taken orally. Clotrimazole is an antifungal medication commonly used in the treatment of fungal infections of both humans and animals such as vaginal yeast infections and ringworm. It also used to treat athlete's foot and jock itch.
Contaminant Sources
  • FooDB Chemicals
  • STOFF IDENT Compounds
  • T3DB toxins
  • ToxCast & Tox21 Chemicals
Contaminant Type
  • 14-alpha Demethylase Inhibitor
  • Amine
  • Anti-Infective Agent, Local
  • Antifungal Agent
  • Drug
  • Food Toxin
  • Growth Inhibitor
  • Metabolite
  • Organic Compound
  • Organochloride
  • Synthetic Compound
Chemical Structure
Synonyms
ValueSource
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazoleChEBI
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazoleChEBI
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazoleChEBI
1-(O-Chlorotrityl)imidazoleChEBI
LotriminChEBI
MycelexChEBI
1-(a-(2-Chlorophenyl)benzhydryl)imidazoleGenerator
1-(Α-(2-chlorophenyl)benzhydryl)imidazoleGenerator
1-(O-Chloro-a,a-diphenylbenzyl)imidazoleGenerator
1-(O-Chloro-α,α-diphenylbenzyl)imidazoleGenerator
(Chlorotrityl)imidazoleHMDB
CanestenHMDB
Canesten 1-day cream combi-pakHMDB
Canesten 1-day therapyHMDB
Canesten 3-day therapyHMDB
Canesten 6-day therapyHMDB
Canesten combi-pak 1-day therapyHMDB
Canesten combi-pak 3-day therapyHMDB
Canesten creamHMDB
Canesten solutionHMDB
CanestineHMDB
ChlotrimazoleHMDB
ClotrimadermHMDB
Clotrimaderm creamHMDB
ClotrimazolHMDB
ClotrimazolumHMDB
Desamix FHMDB
EmpecidHMDB
Fem careHMDB
FemCareHMDB
Gyne lotriminHMDB
Gyne-lotriminHMDB
Gyne-lotrimin 3HMDB
Gyne-lotrimin 3 combination packHMDB
Gyne-lotrimin combination packHMDB
Gyne-lotrimin3HMDB
Gyne-lotrimin3 combination packHMDB
GynixHMDB
Lopac-C-6019HMDB
LotrimaxHMDB
Lotrimin afHMDB
Lotrimin af creamHMDB
Lotrimin af jock-itch creamHMDB
Lotrimin af lotionHMDB
Lotrimin af solutionHMDB
Lotrimin creamHMDB
Lotrimin lotionHMDB
Lotrimin solutionHMDB
LotrisoneHMDB
mono-BaycutenHMDB
MonobaycutenHMDB
MycelaxHMDB
Mycelex 7HMDB
Mycelex creamHMDB
Mycelex gHMDB
Mycelex otcHMDB
Mycelex solutionHMDB
Mycelex trochesHMDB
Mycelex twin packHMDB
Mycelex-7HMDB
Mycelex-7 combination packHMDB
Mycelex-gHMDB
Mycelex: mycosporinrimazoleHMDB
Myclo creamHMDB
Myclo solutionHMDB
Myclo spray solutionHMDB
Myclo-gyneHMDB
MycosporinHMDB
MykosporinHMDB
Neo-zol creamHMDB
OtomaxHMDB
PedisafeHMDB
Prestwick_120HMDB
RimazoleHMDB
TibatinHMDB
TrimystenHMDB
Trivagizole 3HMDB
VeltrimHMDB
KlotrimazoleHMDB
Schering brand OF clotrimazoleHMDB
Bayer brand 1 OF clotrimazoleHMDB
Bayer brand 2 OF clotrimazoleHMDB
FB b 5097HMDB
Bay b 5097HMDB
Clotrimazole schering brandHMDB
KanestenHMDB
Chemical FormulaC22H17ClN2
Average Molecular Mass344.837 g/mol
Monoisotopic Mass344.108 g/mol
CAS Registry Number23593-75-1
IUPAC Name1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole
Traditional Nameclotrimazole
SMILESClC1=CC=CC=C1C(N1C=CN=C1)(C1=CC=CC=C1)C1=CC=CC=C1
InChI IdentifierInChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H
InChI KeyVNFPBHJOKIVQEB-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as triphenyl compounds. These are aromatic compounds containing a triphenyl moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTriphenyl compounds
Sub ClassNot Available
Direct ParentTriphenyl compounds
Alternative Parents
Substituents
  • Triphenyl compound
  • Chlorobenzene
  • Halobenzene
  • Aryl chloride
  • Aryl halide
  • Monocyclic benzene moiety
  • N-substituted imidazole
  • Azole
  • Heteroaromatic compound
  • Imidazole
  • Azacycle
  • Organoheterocyclic compound
  • Organonitrogen compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organopnictogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginExogenous
Cellular Locations
  • Membrane
Biofluid LocationsNot Available
Tissue Locations
  • Skin
PathwaysNot Available
Applications
Biological Roles
Chemical RolesNot Available
Physical Properties
StateSolid
AppearanceWhite powder.
Experimental Properties
PropertyValue
Melting Point154-156°C
Boiling PointNot Available
Solubility29.84 mg/mL
Predicted Properties
PropertyValueSource
Water Solubility0.0015 g/LALOGPS
logP5.48ALOGPS
logP5.84ChemAxon
logS-5.4ALOGPS
pKa (Strongest Basic)6.62ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area17.82 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity103.76 m³·mol⁻¹ChemAxon
Polarizability36.25 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityYesChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
Toxicity Profile
Route of ExposurePoorly and erratically absorbed orally, minimal vaginal or topical absorption.
Mechanism of ToxicityClotrimazole interacts with yeast 14-α demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the membrane. In this way, clotrimazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Clotrimazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel.
MetabolismHepatic (metabolized to inactive metabolites) Half Life: 2 hours
Toxicity ValuesNot Available
Lethal DoseNot Available
Carcinogenicity (IARC Classification)No indication of carcinogenicity to humans (not listed by IARC).
Uses/SourcesFor the local treatment of oropharyngeal candidiasis and vaginal yeast infections, also used in fungal infections of the skin such as ringworm, athlete's foot, and jock itch.
Minimum Risk LevelNot Available
Health EffectsNot Available
SymptomsSymptoms of overdose include erythema, stinging, blistering, peeling, edema, pruritus, urticaria, burning, and general irritation of the skin, and cramps.
TreatmentNot Available
Concentrations
Not Available
External Links
DrugBank IDDB00257
HMDB IDHMDB0001922
FooDB IDFDB022740
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG IDNot Available
BioCyc IDNot Available
METLIN ID1897
PDB IDNot Available
Wikipedia LinkClotrimazole
Chemspider ID2710
ChEBI ID3764
PubChem Compound ID2812
Kegg Compound IDC06922
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis Reference

Buechel, K.H., et al; South African Patent 69/0039; January 3, 1969; assigned to Farben- Buechel, K.H., Regel, E. and Plempel, M.; US. Patent 3,660,577; May 2,1972; and U.S. fabriken Bayer AG, Germany.
Patent 3,705,172; Dec. 5,1972; both assigned to Farbenfabriken Bayer A.G. (Germany).

MSDSLink
General References
1. Lucker PW, Beubler E, Kukovetz WR, Ritter W: Retention time and concentration in human skin of bifonazole and clotrimazole. Dermatologica. 1984;169 Suppl 1:51-5.
2. Schmidt A, Ruhl-Horster B: In vitro susceptibility of Malassezia furfur against azole compounds. Mycoses. 1996 Jul-Aug;39(7-8):309-12.
3. Schmook FP, Meingassner JG, Billich A: Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm. 2001 Mar 14;215(1-2):51-6.
4. https://www.ncbi.nlm.nih.gov/pubmed/?term=18728240
5. https://www.ncbi.nlm.nih.gov/pubmed/?term=24892421